AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Subscribe To Our Newsletter & Stay Updated